Managed Care and Specialty Pharmacy Professionals Identify Barriers and Solutions to Increasing Biosimilar Adoption
Alexandria, Va., April 2019 -- The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies. But formidable barriers, including concerns about safety and efficacy among prescribers and state laws on substitution and interchangeability, have hindered biosimilar adoption. A new survey conducted by AMCP and PRIME Education assesses various strategies that managed care and specialty pharmacy professionals could adopt to overcome such barriers and boost biosimilar utilization. The results were recently published in AMCP’s Journal of Managed Care and Specialty Pharmacy.